BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biktarvy (Bictegravir) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Biktarvy (Bictegravir)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06830668-956@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Biktarvy (Bictegravir): Phase 4 readout est. (NCT06830668)
DESCRIPTION:Biktarvy (Bictegravir)\, phase 4\, HIV.\nStudy: Same-Day Restar
 t of B/F/TAF in HIV Patients After NNRTI Discontinuation\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bictegravir#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06830668
URL:https://assetmemo.bio/drug/bictegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476339-956@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270617
DTEND;VALUE=DATE:20270618
SUMMARY:Biktarvy (Bictegravir): Phase 4 readout est. (NCT07476339)
DESCRIPTION:Biktarvy (Bictegravir)\, phase 4\, HIV.\nStudy: REINItiation of
  Antiretroviral Therapy Using Oral bicTegravir\, emtrIcitAbine and Tenofov
 ir alafenamidE\nEstimated primary completion: 17 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bictegravir#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07476339
URL:https://assetmemo.bio/drug/bictegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939529-956@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Biktarvy (Bictegravir): Phase 1 readout est. (NCT07939529)
DESCRIPTION:Biktarvy (Bictegravir)\, phase 1\, HIV.\nStudy: People With Act
 ive Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effe
 ctiveness\nEstimated primary completion: 31 August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bictegravir#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07939529
URL:https://assetmemo.bio/drug/bictegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
